

Pablo J. Cagnoni, MD , was appointed Senior Vice President and Global Head, Oncology Clinical Development with Novartis Pharmaceuticals Corporation as of October 2009. He is responsible for leading the nearly 300 employees working in Oncology Clinical Development to ensure successful clinical development plans and to establish a Center of Excellence for all clinical activities, including the development of talent within Oncology. In this position, Pablo continues to help find ways to expedite Oncology Global Development trials in order to bring more new therapies to patients faster, leveraging his many strong external relationships with key stakeholders, as well sharing new and innovative ideas to continue to strengthen the clinical function. He also partners closely with the Novartis Oncology Global Program Heads to provide expertise on clinical strategies and to actively manage and ensure the quality of all clinical programs.

Pablo joined Novartis from Allos Therapeutics, Inc. where he served as Senior Vice President and Chief Medical Officer, responsible for clinical research, biometrics and data management, regulatory affairs, project management and pre-clinical development. Pablo led the team that recently obtained the accelerated approval of Folutyn™ (pralatrexate) for the treatment of peripheral T-cell lymphoma.

Prior to that, Pablo was Chief Medical Officer and Vice President, Clinical Research and Medical Affairs at OSI Pharmaceuticals, where he had oversight for all translational and clinical development activities for Tarceva® (erlotinib), OSI-930 (Kit/KDR inhibitor), OSI-817 (Kit/KDR inhibitor) and OSI-906 (IGFIR inhibitor). Pablo led the team responsible for the successful submission and approval for Tarceva's pancreatic cancer indication. Prior to OSI Pharmaceuticals, he served as Vice President and Head of Clinical Development at Allos Therapeutics, Inc. and previous to his industry experience, Pablo was Assistant Professor of Medicine and Assistant Director Pharmacology Laboratory, University of Colorado Bone Marrow Transplant Program.

Pablo earned his Medical Degree from University Buenos Aires School of Medicine. His postgraduate training includes a residency in internal medicine at Centro de Educacion Medica e Investigaciones Clinicas (CEMIC), Buenos Aires, a fellowship in Hematology and Oncology as well as serving as Chief Fellow, Division of Hematology, Department of Medicine at Mount Sinai Medical Center, New York, in addition to other appointments. Pablo is widely published, with more than 70 publications and abstracts.